NYSEARCA:IHE iShares U.S. Pharmaceuticals ETF (IHE) Price, Holdings, & News $102.53 +0.19 (+0.19%) Closing price 09/25/2026 04:10 PM EasternExtended Trading$102.52 -0.01 (-0.01%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest About iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IHE alerts:Sign Up Key Stats Today's Range$101.49▼$102.7850-Day Range$98.85▼$108.1652-Week Range$69.68▼$108.66Volume74,468 shsAverage Volume156,962 shsMarket Capitalization$1.67 billionAssets Under Management$1.67 billionDividend Yield1.39%Net Expense Ratio0.38%Aggregate RatingModerate Buy ETF Overview iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors. Read More iShares U.S. Pharmaceuticals ETF ExpensesTypeIHEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.38%0.55%0.57%0.50%0.53%Other Expenses0.00%0.52%0.53%0.60%0.54%Total Expense0.38%0.76%0.75%0.75%0.73%Fee Waiver0.00%-0.85%-0.67%-0.78%-0.68%Net Expense0.38%0.58%0.63%0.57%0.60% Receive IHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares U.S. Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IHE ETF News HeadlinesIHE: Innovation Supports The Outlook, Valuation Limits ConvictionSeptember 11, 2026 | seekingalpha.comIHE: Large-Cap Pharma Cools After A Hot SummerSeptember 10, 2026 | seekingalpha.comIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed forces. One writer says the request echoes a secret January meeting outside Washington, D.C., where an anonymous source described American military protection as part of something much bigger, involving Trump, Iran, and potentially trillions of dollars.September 26 at 1:00 AM | Banyan Hill Publishing (Ad)(IHE) iShares U.S. Pharmaceuticals ETFSeptember 9, 2026 | sa.investing.comIs the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?September 8, 2026 | finance.yahoo.comDoes iShares Pharma ETF Offer Superior Returns to Invesco's Equal Weight Healthcare Fund?September 8, 2026 | fool.comSee More Headlines IHE ETF - Frequently Asked Questions How have IHE shares performed this year? iShares U.S. Pharmaceuticals ETF's stock was trading at $84.83 on January 1st, 2026. Since then, IHE stock has increased by 20.9% and is now trading at $102.53. When did iShares U.S. Pharmaceuticals ETF's stock split? Shares of iShares U.S. Pharmaceuticals ETF split before market open on Thursday, March 7th 2024.The 3-1 split was announced on Thursday, March 7th 2024. The newly created shares were issued to shareholders after the market closes on Thursday, March 7th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares U.S. Pharmaceuticals ETF's major shareholders? iShares U.S. Pharmaceuticals ETF's top institutional shareholders include Insight Wealth Strategies LLC (1.07%), Concurrent Investment Advisors LLC (0.33%), Tidal Investments LLC (0.23%) and Schuylkill Financial LLC (0.06%). How do I buy shares of iShares U.S. Pharmaceuticals ETF? Shares of IHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares U.S. Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares U.S. Pharmaceuticals ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), Visa (V), Adobe (ADBE), Lam Research (LRCX) and Advanced Micro Devices (AMD). Fund Details IssueriShares Fund NameiShares U.S. Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:IHE Inception Date5/1/2006 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason Webwww.iShares.com PhoneN/AFund Focus Asset ClassEquity BenchmarkDow Jones U.S. Select Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings57 Fund Statistics Assets Under Management$1.67 billion Average Daily Volume$180.72 thousand Discount/Premium0.04% Administrator, Advisor and Custodian AdministratorCitibank, N.A. AdvisorBlackRock Fund Advisors CustodianCitibank, N.A. DistributorBlackRock Investments, LLC Transfer AgentCitibank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableN/A Short Interest334,001 shs Miscellaneous Outstanding Shares16,300,000Beta0.49 Creation Unit50,000 Creation Fee$306.00 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report Top 10 IHE HoldingsJohnson & Johnson (NYSE:JNJ)Holding Weight: 23.61%Eli Lilly and Company (NYSE:LLY)Holding Weight: 21.09%Merck & Co., Inc. (NYSE:MRK)Holding Weight: 5.13%Bristol Myers Squibb (NYSE:BMY)Holding Weight: 4.82%Pfizer (NYSE:PFE)Holding Weight: 4.52%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 4.52%Viatris (NASDAQ:VTRS)Holding Weight: 4.52%Zoetis (NYSE:ZTS)Holding Weight: 3.78%Jazz Pharmaceuticals (NASDAQ:JAZZ)Holding Weight: 3.49%Elanco Animal Health (NYSE:ELAN)Holding Weight: 2.60%Full Holdings DetailsIHE Sector ExposureIHE Industry Exposure This page (NYSEARCA:IHE) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredDid you forget to grab this?Most beginners stay stuck on the sidelines for years because no one shows them the simple steps between being ...Profits Run | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares U.S. Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares U.S. Pharmaceuticals ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
